Format

Send to

Choose Destination
Nefrologia. 2015;35(2):207-17. doi: 10.1016/j.nefro.2015.05.022. Epub 2015 Jun 23.

Use of sevelamer in chronic kidney disease: beyond phosphorus control.

[Article in English, Spanish]

Author information

1
Servicio de Nefrología. Fundación Jiménez Díaz. Madrid (España).
2
Servicio de Nefrología. Fundación Jiménez Díaz. Universidad Autónoma de Madrid. Madrid (España).
3
Servicio de Nefrología. Fundación Jiménez Díaz. Universidad Autónoma de Madrid. Madrid (España). Electronic address: egparra@fjd.es.

Abstract

Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects, beyond hyperphosphataemia control, including actions on inflammation, oxidative stress, lipid profile and atherogenesis, vascular calcification, endothelial dysfunction and the reduction of several uremic toxins. This is the biological basis for its global effect on cardiovascular morbidity and mortality in patients with chronic kidney disease. This review focuses on these pleiotropic actions of sevelamer and their impact on cardiovascular health, with the experience published after more than ten years of clinical expertise.

KEYWORDS:

Efectos pleiotrópicos; Fósforo; Gut; Inflamación e intestino; Inflammation; Phosphate; Pleiotropic effects; Sevelamer

PMID:
26300515
DOI:
10.1016/j.nefro.2015.05.022
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center